1. Home
  2. IMCC vs GTBP Comparison

IMCC vs GTBP Comparison

Compare IMCC & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMCC
  • GTBP
  • Stock Information
  • Founded
  • IMCC 1980
  • GTBP 1965
  • Country
  • IMCC Israel
  • GTBP United States
  • Employees
  • IMCC N/A
  • GTBP N/A
  • Industry
  • IMCC Medicinal Chemicals and Botanical Products
  • GTBP Biotechnology: Pharmaceutical Preparations
  • Sector
  • IMCC Health Care
  • GTBP Health Care
  • Exchange
  • IMCC Nasdaq
  • GTBP Nasdaq
  • Market Cap
  • IMCC 7.5M
  • GTBP 4.9M
  • IPO Year
  • IMCC N/A
  • GTBP N/A
  • Fundamental
  • Price
  • IMCC $2.20
  • GTBP $2.12
  • Analyst Decision
  • IMCC
  • GTBP Strong Buy
  • Analyst Count
  • IMCC 0
  • GTBP 1
  • Target Price
  • IMCC N/A
  • GTBP $11.00
  • AVG Volume (30 Days)
  • IMCC 16.0K
  • GTBP 236.8K
  • Earning Date
  • IMCC 03-27-2025
  • GTBP 03-25-2025
  • Dividend Yield
  • IMCC N/A
  • GTBP N/A
  • EPS Growth
  • IMCC N/A
  • GTBP N/A
  • EPS
  • IMCC N/A
  • GTBP N/A
  • Revenue
  • IMCC $38,042,859.00
  • GTBP N/A
  • Revenue This Year
  • IMCC $22.59
  • GTBP N/A
  • Revenue Next Year
  • IMCC $32.86
  • GTBP N/A
  • P/E Ratio
  • IMCC N/A
  • GTBP N/A
  • Revenue Growth
  • IMCC N/A
  • GTBP N/A
  • 52 Week Low
  • IMCC $1.50
  • GTBP $1.72
  • 52 Week High
  • IMCC $8.10
  • GTBP $10.66
  • Technical
  • Relative Strength Index (RSI)
  • IMCC 43.43
  • GTBP 43.06
  • Support Level
  • IMCC $2.11
  • GTBP $2.03
  • Resistance Level
  • IMCC $2.42
  • GTBP $2.38
  • Average True Range (ATR)
  • IMCC 0.18
  • GTBP 0.23
  • MACD
  • IMCC 0.01
  • GTBP 0.01
  • Stochastic Oscillator
  • IMCC 12.85
  • GTBP 30.85

About IMCC IM Cannabis Corp.

IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.

About GTBP GT Biopharma Inc.

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.

Share on Social Networks: